Vaxcyte shares jump over 85% premarket as pneumococcal vaccine hits late-stage trial goal

The premarket move reflects a binary clinical readout, not a commercial one: meeting a late-stage trial goal clears the main scientific risk, but pricing, reimbursement and competitive positioning in pneumococcal vaccines remain unproven. The reaction is concentrated in a single name, so the read-through to the broader biotech tape is limited. Whether the trial result translates into a durable re-rating, or fades once the initial repricing settles, is the open question.